APO-OXYCODONE CR 10 MG
OXYCODONE HYDROCHLORIDE : 10 MG · DIN 02366754 · APOTEX INC
Health Canada status: MARKETED
What is APO-OXYCODONE CR?
APO-OXYCODONE CR 10 MG contains OXYCODONE HYDROCHLORIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02366754, held by APOTEX INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 17-May-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-OXYCODONE CR used for?
Management of pain severe enough to require daily, continuous, long-term opioid treatment that is opioid-responsive and for which alternative options are inadequate. Not for as-needed (prn) use.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02366754 |
|---|---|
| Brand name | APO-OXYCODONE CR |
| Generic / active ingredient | OXYCODONE HYDROCHLORIDE : 10 MG |
| Manufacturer | APOTEX INC |
| Strength | 10 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA05 OXYCODONE |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-May-2018 |
| Original market date | 2012-11-26 00:00:00 |
How is it administered?
Swallow whole q12h. Initial dose for opioid-naive: 10 mg q12h. Titrate every 24-36 hours. 60 mg and 80 mg tablets are for opioid-tolerant patients only. Taper gradually to discontinue.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section 11 was not fully included), but typically store at room temperature.
How is it supplied?
Bottles of 50 and 100 tablets.
Contraindications
Hypersensitivity; GI obstruction; suspected surgical abdomen; acute/severe asthma; respiratory depression; acute alcoholism; convulsive disorders; head injury; MAO inhibitors; pregnancy/breastfeeding.
Warnings and precautions
Risks of addiction, abuse, misuse, and fatal overdose. Life-threatening respiratory depression. Do not crush/chew. Risk of Neonatal Opioid Withdrawal Syndrome. Avoid alcohol.
What can be used instead?
Other Canadian products sharing ATC code N02AA05 OXYCODONE. 28 of 68 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OXYCODONE CR | 15 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02394766 |
| APO-OXYCODONE CR | 20.0 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02366762 |
| APO-OXYCODONE CR | 30 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02394774 |
| APO-OXYCODONE CR | 40 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02306530 |
| APO-OXYCODONE CR | 5.0 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02366746 |
| APO-OXYCODONE CR | 60 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02394782 |
| APO-OXYCODONE CR | 80.0 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02366789 |
| OXY.IR | 10 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 02240131 |
| OXY.IR | 20 MG | TABLET (IMMEDIATE RELEASE) | PURDUE PHARMA | MARKETED | DIN 02240132 |
| OXY.IR | 5 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 02231934 |
Who else supplies OXYCODONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OXYCODONE appears in 240 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.